Skip to main content
SpringerLink
Log in

47th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, 3–7 June 2011

Focus on Pediatric Oncology

  • Meeting Report
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ladenstein RL, Poetscheger U, Luksch R, et al. Busulphan-melphalan is the superior myeloablative therapy (MAT) for high risk neuroblastomas: results from HRNBL1/SIOPEN trial [abstract no. 3]. J Clin Oncol 2011; 29 (18 Suppl. 2)

    Google Scholar 

  2. Navid F, Barfield RC, Handgretinger R, et al. A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children with refractory or recurrent neuroblastomas: early-phase evaluation [abstract no. 9523]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  3. National Cancer Institute. Monoclonal antibody Ch 14.18, sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma [ClinicalTrials.gov identifier NCT01041638]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 28]

  4. Ganeshan VR, Schor NF. Pharmacologic management of high-risk neuroblastomas in children. Pediatr Drugs 2011; 13(4): 245–55

    Article  Google Scholar 

  5. Weiser D, Laudenslaer M, Rappaport E, et al. Stratification of patients with neuroblasoma for targeted ALK inhibitor therapy [abstract no. 9514]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  6. Larsen EC, Salzer WL, Devidas M, et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children’s Oncology Group Study AALL0232 [abstract no. 3]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  7. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood 2007; 109(3): 926–35

    Article  PubMed  CAS  Google Scholar 

  8. Winick NJ, Salzer WL, Devidas M, et al. Dexamethasone (DEX) versus prednisone (PRED) during indication for children with high-risk acute lymphoblastic leukemia (HR-ALL): report from the Children’s Oncology Group Study AALL0232 [abstract no. 9504]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  9. Mascarenhas L, Felgenhauer JL, Bond MC, et al. Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma family of tumors: a Children’s Oncology Group trial [abstract no. 9526]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  10. Oberlin O, Le Deley M, Dirksen U, et al. andomized comparison of VAC versus VAI chemotherapy (CT) as consolidation for standard risk (SR) Ewing sarcoma tumor (ES): results of the Euro-EWING.99-R1 trial [abstract no. 9517]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  11. Walterhouse D, Papp AS, Meza JL, et al. Shorter duration therapy that includes incristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): a report from the Children’s Oncology Group (COG) [abstract no. 9516]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  12. Hagleitner M, Hoogerbrugge P, Schreuder BWB, et al. Relevance of germ-line genetic variations for treatment response in pediatric osteosarcoma patients [abstract no. 9518]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  13. Baruchel S, Wu B, Mokhtari RB, et al. Surrogate biomarkers of antiangiogenesis in Children’s Oncology Group (COG) phase I trials [abstract no. 9502]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  14. Glade Bender JL, Lee A, Adamson PC, et al. Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815: Children’s Oncology Group Phase I Consortium Trial [abstract no. 9501]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

  15. Santana VM, Baker SD, McCarville B, et al. Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors [abstract no. 9500]. J Clin Oncol 2011; 29 (15 Suppl. 1)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, Auckland, New Zealand

    Michelle I. Wilde

Authors
  1. Michelle I. Wilde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilde, M.I. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, 3–7 June 2011. Pediatr-Drugs 13, 325–328 (2011). https://doi.org/10.2165/11596120-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11596120-000000000-00000

Keywords

Search

Navigation